Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.48
+$0.06 · +2.48%
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Previous close
$2.48
+$0.06 · +2.48%
Regular session · ET · Market data may be delayed.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Day range
Current $2.48
52-week range
Current $2.48
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
32
Expensive
Sentiment
45
Mixed
Risk
51
Elevated Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Day range
Current $2.48
52-week range
Current $2.48
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 66.27M USD | 51.96M USD | 30.31M USD | 27.08M USD | 23.74M USD |
| Selling, general, and administrative | 16.98M USD | 18.61M USD | 12.69M USD | 12.7M USD | 13.13M USD |
| Operating expenses | 83.25M USD | 70.58M USD | 43M USD | 88.43M USD | 36.87M USD |
| Depreciation and amortization | 313K USD | 359K USD | 374K USD | 373K USD | 195K USD |
| Operating income | −83.25M USD | −70.58M USD | −43M USD | −88.43M USD | −36.87M USD |
| Net income | −45.62M USD | −36.18M USD | −116.54M USD | −87.97M USD | −34.51M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.00
182.26% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 5, 2020 | 1:18 | — | — |
Stock split | May 11, 2017 | 1:9 | — | — |
Effective Oct 5, 2020
1:18
Effective May 11, 2017
1:9
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.4M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM5.04M0.01%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF2.55M0.00%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO1.74M0.01%13.97B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO1.32M0.01%18B USD0.06%$112.66+0.50%
Dimensional - US Small Cap ETFDFAS609.19K0.00%33.87B USD0.31%$78.35+0.32%
iShares Micro-Cap ETFIWC584.23K0.04%1.32B USD0.60%$183+0.11%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC270.82K0.03%1.04B USD0.20%$86.29+0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
